

GYRUS MEDICAL DOCUMENT No. 813740

Gyrus Medical Limited
Cardiff CF3 0LT, UK
510k Premarket Notification
November, 1999

510(k) Summary of Safety and Effectiveness

Statement

Information supporting claims of substantial equivalence, as defined under the Federal Food, Drug, and Cosmetic Act, respecting safety and effectiveness is summarized below. For the convenience of the Reviewer, this summary is formatted in accordance with the Agency's final rule "...510(k) Summaries and 510(k) Statements..." (21 CFR 807) and can be used to provide a substantial equivalence summary to anyone requesting it from the Agency.

MODIFIED DEVICE NAME: Gyrus Hysteroscopic Resectoscope
Accessories Visual Obturator and Rotating
Outer Sheath

PREDICATE DEVICE NAME: COMEG Endoscopy Resectoscope

Device
Description

The Gyrus Hysteroscopic Resectoscope that we intend to market employs an electrode specific resectoscope-working element. All other sheaths, etc., are standard COMEG components. A "Quick Connection" feature is used to attach the working element to the sheath.

Endoscopic electrosurgical instruments and accessories are described under "Endoscope and Accessories" in 21 CFR 876.1500, and Hysteroscopes and described in 21 CFR 884.1690.

The Hysteroscopic Resectoscope is intended to enable the viewing of the cervical canal and the uterine cavity for the purpose of performing diagnostic and surgical procedures.

The surgeon performs the examination through the cervical canal. The working elements are the devices that house and control various electrodes and lasers used to remove, cut, coagulate, and transect tissue. The surgeon controls the back and forth movement of the electrode using finger controls. The working elements also house a telescope for visualization. Current is transmitted to the electrode through a high frequency cable.

Continued on next page

Device
 Description (Cont'd)

These devices are composed of stainless steel, stainless steel chrome plated, plastic and brass chrome plated parts.

The Gyrus Hysteroscopic Resectoscope as cleared in K982771, is identical to the COMEG Resectoscope cleared via K971882, with the working element modified to fit the Gyrus Medical Ltd. electrode. Endoscopic electrosurgical instruments and accessories are described in endoscope and accessories, 21 CFR 876.1500, and endoscope ESU units and accessories are described in 21 CFR 876.4300. Hysteroscopes are described in 21 CFR 884.1690.

The Rotating Outer Sheath connection for the working element is of a "snap-on" construction, identical to the cleared device. The principal difference is in the rotating collar which allows 360 degree rotation of the fluid inlet.

The Visual Obturator provides the same functionality as the standard obturator facilitating insertion to the uterus. In addition, the Visual Obturator allows use of the hysteroscope (telescope) during insertion, allowing visualization.

Intended Use

The Gyrus Hysteroscopic Resectoscope is intended to enable the viewing of the cervical canal and the uterine cavity for the purpose of performing diagnostic and surgical procedures. The surgical applications include tissue cutting, removal, and dissection as required or encountered in gynecologic hysteroscopic electrosurgical procedures for the treatment of intrauterine myomas, polyps, adhesions, and septa.

Indications Statement

The Gyrus Hysteroscopic Resectoscope is used to permit the direct Viewing of the cervical canal and the uterine cavity for the purpose of performing diagnostic and surgical procedures.

Technological
 Characteristics

The modified device has the same technological characteristics as the predicate devices. The form, fit and function is similar.

Performance Data

Preclinical as well as bench top testing has been performed to verify that The product meets the performance requirements described. This substantiates the efficacy of the resectoscope for the hysteroscopic usage.

Continued on next page

GYRUS MEDICAL DOCUMENT No. 813740

Gyrus Medical Limited
Cardiff CF3 0LT, UK
510k Premarket Notification
November, 1999

Conclusion

Based upon the 510(k) summaries and 510(k) statements (21 CFR 807) and the information provided herein, we conclude that the new device is substantially equivalent to the predicate devices under the Federal Food, Drug, and Cosmetic Act.

Contact

David Kay
Director
Regulatory Affairs and Quality Assurance
Gyrus Medical Ltd.
Fortran Road
St. Mellons
Cardiff, CF3 0LT
United Kingdom

Date

November 4, 1999



DEC - 3 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. David Kay
Director, Regulatory Affairs & Quality Assurance
Gyrus Medical Limited
Fortran Road
St Mellons
Cardiff CF3 0LT
UK

Re: K993749
Hysteroscopic Rotating Sheath and Visual Obturator
Dated: November 4, 1999
Receive: November 5, 1999
Regulatory Class: II
21 CFR §884.1698/Procode: 85HIH

Dear Mr. Kay:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

CAPT Daniel G. Schultz, M.D.
Acting Director, Division of Reproductive,
Abdominal, Ear, Nose and Throat,
and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number (if known): K993749

Device Name: Gyrus Hysteroscopic Resectoscope

Indications for Use: Used to permit direct viewing of the cervical canal and the uterine Cavity for the purpose of performing diagnostic and surgical procedures. As used with the Gynecare Versapoint System, the indications for use include:

- Excision on intrauterine myomas
- Excision of intrauterine polyps
- Lysis of intrauterine adhesions
- Incision of uterine septa


When used for resection of endometrial tissue with the G-VAP Electrode, the device is indicated for Endometrial Ablation.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use OR Over-The-Counter Use

(Optional Format 1-2-96)


 (Division Sign-Off)
 Division of Reproductive, Abdominal, ENT,
 and Radiological Devices
 510(k) Number K993749